Product Information

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB is a generic product labeled by ANI Pharmaceuticals, Inc., priced at $0.6313 per EA under NDC 62559066190. Its NADAC has been published 406 times since Feb 13, 2019.

FDA first approved this application on Sep 5, 2000. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB

Candesartan Cilexetil and Hydrochlorothiazide
$0.6313per EA

Strength

32; 12.5 mg/1; mg/1

NDC

62559066190

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

11/18/2026

Approval Type

Authorized Generic (NDA)

FDA Application

NDA021093

FDA Approved

9/5/2000

TE Code

AB

On Market Since

9/26/2018

Pharmacological Classes

Angiotensin 2 Receptor Antagonists
Angiotensin 2 Receptor Blocker
Increased Diuresis
Thiazide Diuretic
Thiazides

Price Statistics

The NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has been published 406 times since Feb 13, 2019, and over the history we have for it it has declined 73.7%. The table below summarizes its recorded NADAC range and movement.

Current price$0.6313 per EA
All-time high$3.1731 (Mar 13, 2019)
All-time low$0.6313 (Nov 18, 2026)
52-week high$1.2226
52-week low$0.6313
Median price$1.5155
Average price$1.6044
Largest weekly change+48.6% (Aug 18, 2021)
Weeks tracked406
Tracking sinceFeb 13, 2019

Price History

1W

-13.4%

1M

-13.4%

3M

-30.0%

6M

-46.6%

1Y

-42.7%

3Y

-61.5%

5Y

-63.2%

All

-73.7%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

The current National Average Drug Acquisition Cost (NADAC) for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB, manufactured by ANI Pharmaceuticals, Inc., is $0.6313 per EA (NDC 62559066190), effective Nov 18, 2026.

How has the price of CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB changed over time?

Over the history we have for it, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has declined 73.7%. It has been tracked across 406 weekly CMS publications since Feb 13, 2019.

What are the highest and lowest recorded NADAC prices for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

Since Feb 13, 2019, the NADAC for CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB has ranged from a low of $0.6313 (Nov 18, 2026) to a high of $3.1731 (Mar 13, 2019), with a median of $1.5155 per EA.

Are there cheaper alternatives to CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB in a comparable dosage form, but none are currently priced below it.

Who manufactures CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB?

CANDESARTAN-HYDROCHLOROTHIAZIDE 32-12.5 MG TB (NDC 62559066190) is labeled by ANI Pharmaceuticals, Inc., and CMS classifies it as a generic product.